ArticleSpectrochimica acta. Part A, Molecular and biomolecular spectroscopy2023
Eco-friendly spectrophotometric methods for determination of remdesivir and favipiravir; the recently approved antivirals for COVID-19 treatment.
Article in Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Development and validation of a RP-HPLC method for simultaneous determination of five COVID-19 antiviral drugs in pharmaceutical formulations.Scientific reports · 2025Article
- Eco-Friendly Synchronous Spectrofluorimetric Method for Simultaneous Determination of Remdesivir and Acetyl Salicylic Acid in Spiked Human Plasma.Journal of fluorescence · 2025Article
- Utility of Microwave-Synthesized Silver Nano Particles as Spectrofluorimetric Sensors for the Determination of Nano Concentrations of Favipravir: Application to Dosage Forms and Spiked Human Plasma.Journal of fluorescence · 2025Article
- Article
- A green three-ratio manipulating spectrophotometric approaches for the determination of a binary mixture of pantoprazole and domperidone.BMC chemistry · 2025Article
- Ecofriendly spectrophotometric methods for simultaneous determination of remdesivir and moxifloxacin hydrochloride as co administered drugs in corona virus treatment.Scientific reports · 2025Article
- Article
- Application of signal processing techniques for the spectroscopic analysis of dolutegravir and lamivudine: a comparative assessment and greenness appraisal.BMC chemistry · 2024Article
- Insights into the sustainability of liquid chromatographic methods for favipiravir bioanalysis: a comparative study.RSC advances · 2024Review
- An eco-friendly and cost-effective HPTLC method for quantification of COVID-19 antiviral drug and co-administered medications in spiked human plasma.Scientific reports · 2024Article
- Article
- Recent analytical methodologies for the determination of anti-covid-19 drug therapies in various matrices: a critical review.RSC advances · 2023Review
- Simultaneous spectrofluorimetic determination of remdesivir and simeprevir in human plasma.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Remdesivir (REM) and Favipiravir (FAV) are recently approved antivirals prescribed in severely ill COVID-19 patients. Therefore, development of new, simple, rapid, sensitive, and selective methods for analysis of such drugs in their pharmaceutical formulations will be highly advantageous. Herein, we have developed different spectrophotometric methods for analysis of the studied analytes. Method I is based on direct spectrophotometric analysis of REM and FAV in ethanol at λ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.